Analysts Set Twist Bioscience Co. (NASDAQ:TWST) Price Target at $50.40

Twist Bioscience Co. (NASDAQ:TWST) has been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $50.40.

A number of brokerages recently commented on TWST. JPMorgan Chase & Co. dropped their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 6th. Guggenheim restated a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. The Goldman Sachs Group dropped their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird dropped their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. Finally, Barclays dropped their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th.

Twist Bioscience Trading Down 0.3%

Shares of TWST stock opened at $33.52 on Friday. Twist Bioscience has a 52-week low of $27.12 and a 52-week high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The company has a 50-day simple moving average of $34.05 and a two-hundred day simple moving average of $41.62. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -9.92 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Research analysts anticipate that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 936 shares of the firm’s stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $27,846.00. Following the sale, the chief financial officer now owns 106,018 shares in the company, valued at approximately $3,154,035.50. This trade represents a 0.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,726 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the sale, the chief executive officer now owns 660,966 shares in the company, valued at approximately $27,549,062.88. This trade represents a 0.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,920 shares of company stock worth $814,067 in the last three months. 3.01% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in TWST. Versant Capital Management Inc grew its holdings in Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after acquiring an additional 580 shares during the last quarter. GAMMA Investing LLC grew its holdings in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after acquiring an additional 303 shares during the last quarter. Van ECK Associates Corp grew its holdings in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares during the last quarter. Banque Transatlantique SA bought a new stake in Twist Bioscience in the 4th quarter worth $43,000. Finally, GF Fund Management CO. LTD. bought a new stake in Twist Bioscience in the 4th quarter worth $58,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.